

A RESOLUTION encouraging WellCare to improve its formulary for coverage of Attention Deficit Hyperactivity Disorder medications.

WHEREAS, Vyvanse is an important, safe medicine for treating Attention Deficit Hyperactivity Disorder; and

WHEREAS, Vyvanse has a formulation that does not allow it to be abused; and

WHEREAS, this formulation greatly decreases the risk that it will be diverted for improper use; and

WHEREAS, Vyvanse's formulation is also tamper-resistant, because it utilizes the liver and GI tract to implement its active ingredient; and

WHEREAS, using Vyvanse 12-hour instead of the current equivalents reimbursed by WellCare would allow the use of only one drug instead of two, a long-acting and another short-acting equivalent; and

WHEREAS, using Vyvanse 12-hour instead of the currently preferred equivalents listed by WellCare would provide a safe medication that works for 12 hours instead of three to eight hours provided by the current preferred equivalents; and

WHEREAS, Vyvanse would not require a second dosing in most situations as do the current equivalents reimbursed by WellCare; and

WHEREAS, the current formulary utilized by WellCare that emphasizes use of preferred equivalents that are not Vyvanse 12-hour frequently causes providers to need to prescribe a second prescription to the patient that erases any cost savings achieved or reported by the Medicaid managed care organization, and potentially exposes the Medicaid member to additional side effects; and

WHEREAS, the other Medicaid managed care organizations contracted to provide care to our Medicaid population, such as Passport, make Vyvanse available on their preferred formulary to members living with Attention Deficit Hyperactivity Disorder; and

WHEREAS, WellCare listed Vyvanse on its preferred formulary until September 1, 2015; and

WHEREAS, the current equivalents reimbursed by WellCare are easily diverted and may be used improperly;

NOW, THEREFORE,

*Be it resolved by the House of Representatives of the General Assembly of the Commonwealth of Kentucky:*

➔Section 1. This august body does hereby encourage WellCare to treat our citizens living with Attention Deficit Hyperactivity Disorder with the safest and least divertible medicine available.

➔Section 2. Vyvanse should be made available on the preferred formulary to the Medicaid members treated by WellCare, just as Vyvanse is available to the Medicaid members treated by the other Medicaid managed care organizations providing services in Kentucky.